- Home
- LNZA vs RNTX Comparison
LNZA vs RNTX Comparison
Compare LNZA & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNZA
- RNTX
- Stock Information
- Founded
- LNZA 2005
- RNTX 2001
- Country
- LNZA United States
- RNTX United States
- Employees
- LNZA N/A
- RNTX N/A
- Industry
- LNZA Major Chemicals
- RNTX Biotechnology: Pharmaceutical Preparations
- Sector
- LNZA Industrials
- RNTX Health Care
- Exchange
- LNZA Nasdaq
- RNTX Nasdaq
- Market Cap
- LNZA 43.7M
- RNTX 40.3M
- IPO Year
- LNZA N/A
- RNTX N/A
- Fundamental
- Price
- LNZA $0.20
- RNTX $2.05
- Analyst Decision
- LNZA Hold
- RNTX
- Analyst Count
- LNZA 2
- RNTX 0
- Target Price
- LNZA $2.00
- RNTX N/A
- AVG Volume (30 Days)
- LNZA 988.3K
- RNTX 45.2K
- Earning Date
- LNZA 05-19-2025
- RNTX 05-15-2025
- Dividend Yield
- LNZA N/A
- RNTX N/A
- EPS Growth
- LNZA N/A
- RNTX N/A
- EPS
- LNZA N/A
- RNTX N/A
- Revenue
- LNZA $48,831,000.00
- RNTX N/A
- Revenue This Year
- LNZA $86.52
- RNTX N/A
- Revenue Next Year
- LNZA N/A
- RNTX N/A
- P/E Ratio
- LNZA N/A
- RNTX N/A
- Revenue Growth
- LNZA N/A
- RNTX N/A
- 52 Week Low
- LNZA $0.14
- RNTX $1.35
- 52 Week High
- LNZA $3.26
- RNTX $4.40
- Technical
- Relative Strength Index (RSI)
- LNZA 39.55
- RNTX N/A
- Support Level
- LNZA $0.22
- RNTX N/A
- Resistance Level
- LNZA $0.27
- RNTX N/A
- Average True Range (ATR)
- LNZA 0.03
- RNTX 0.00
- MACD
- LNZA 0.00
- RNTX 0.00
- Stochastic Oscillator
- LNZA 5.26
- RNTX 0.00
About LNZA LanzaTech Global Inc.
LanzaTech Global Inc is a carbon management company transforming waste carbon into sustainable fuels, fabrics, packaging, and nutrition. Its goal is to advance a circular economy where carbon is reused rather than wasted, reducing reliance on virgin fossil resources and supporting supply chain resilience. The company operates in North America, Europe, Middle East, Africa (EMEA), Asia, and Australia.
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.